401 General Military Hospital Of Athens
- Address
- lock Available on a paid plan
401 General Military Hospital Of Athens - Neurological & Autoimmune Research Center
The 401 General Military Hospital of Athens is a leading clinical research institution specializing in advanced therapeutic trials for neurological disorders and autoimmune conditions. The center demonstrates exceptional expertise in multiple sclerosis research, conducting cutting-edge studies across all disease subtypes including relapsing, primary progressive, and secondary progressive forms. Their research portfolio encompasses novel biologic therapies and targeted immunomodulatory treatments designed to prevent disability progression and improve long-term patient outcomes.
- Multiple Sclerosis (relapsing, primary progressive, and secondary progressive forms) with focus on BTK inhibitors, anti-CD20 antibodies, and novel immunomodulatory agents
- Autoimmune neurological disorders including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Bullous Pemphigoid
- Respiratory diseases including moderate-to-severe asthma with emphasis on preventing lung function decline
- Oncology thromboprophylaxis studies in advanced pancreatic cancer patients
The hospital's research infrastructure supports comprehensive Phase 2 and Phase 3 clinical trials evaluating both novel therapeutic compounds and optimized dosing strategies for approved medications. With particular strength in long-term extension studies, the center provides critical data on sustained efficacy and safety profiles of emerging treatments. Additional research activities include therapeutic equivalence studies for dermatological conditions, ophthalmic research in glaucoma management, and specialized investigations in venous thromboembolism prevention for cancer patients undergoing chemotherapy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 77 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 74 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in 401 General Military Hospital Of Athens
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Non-Inferiority Study Comparing Brimonidine Tartrate and Timolol Fixed-Dose Combination Eye Drops to an Active Comparator in Patients with Open-Angle Glaucoma or Ocular Hypertension | OmniVision GmbH | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 77 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Upadacitinib | 3 | Unknown | 2019-01-02 | 2023-10-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.